Jefferies Assigns 'Buy' Tag to Molbio Diagnostics, Shares Jump 9%

Business Standard Markets · stocks

Molbio Diagnostics shares surged 9 per cent after Jefferies initiated coverage with a 'Buy' rating, citing its innovation-led model. The investment bank set a target price of ₹1,600, projecting a 27 per cent upside. Jefferies highlighted Molbio's successful commercialization of its Point-of-Care molecular diagnostics platform, Truenat, and its robust product pipeline. The company is expected to see strong growth driven by expansion in India and overseas, alongside new product rollouts. Jefferies anticipates significant revenue and profit growth in the coming years.